These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 21218018)

  • 21. [Application of effective antigen combinations in childhood B lineage acute lymphoblastic leukemia].
    Liu Y; Tang JY; Xu C; Gu LJ; Xue HL; Chen J; Pan C; Dong L; Zhou M
    Zhonghua Er Ke Za Zhi; 2009 May; 47(5):366-70. PubMed ID: 19573409
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [A tal-1 deletion as real-time quantitative polymerase chain reaction target for detection of minimal residual disease in T-lineage acute lymphoblastic leukemia].
    Wang L; Zhang LP; Li ZG; Cheng YF; Tian KG; Lu AD
    Zhonghua Er Ke Za Zhi; 2005 Mar; 43(3):170-3. PubMed ID: 15833185
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Minimal residual disease monitoring by flow cytometry in children with acute lymphoblastic leukemia].
    Popov AM; Verzhbitskaia TIu; Tsaur GA; Shorikov EV; Savel'ev LI; Tsvirenko SV; Fechina LG
    Klin Lab Diagn; 2010 Aug; (8):36-41. PubMed ID: 20886718
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Flow-cytometric minimal residual disease monitoring in blood predicts relapse risk in pediatric B-cell precursor acute lymphoblastic leukemia in trial AIEOP-BFM-ALL 2000.
    Schumich A; Maurer-Granofszky M; Attarbaschi A; Pötschger U; Buldini B; Gaipa G; Karawajew L; Printz D; Ratei R; Conter V; Schrappe M; Mann G; Basso G; Dworzak MN;
    Pediatr Blood Cancer; 2019 May; 66(5):e27590. PubMed ID: 30561169
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia.
    Ravandi F; Jorgensen J; Borthakur G; Jabbour E; Kadia T; Pierce S; Brandt M; Wang S; Konoplev S; Wang X; Huang X; Daver N; DiNardo C; Andreeff M; Konopleva M; Estrov Z; Garcia-Manero G; Cortes J; Kantarjian H
    Cancer; 2017 Feb; 123(3):426-435. PubMed ID: 27657543
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow.
    Basso G; Veltroni M; Valsecchi MG; Dworzak MN; Ratei R; Silvestri D; Benetello A; Buldini B; Maglia O; Masera G; Conter V; Arico M; Biondi A; Gaipa G
    J Clin Oncol; 2009 Nov; 27(31):5168-74. PubMed ID: 19805690
    [TBL] [Abstract][Full Text] [Related]  

  • 27. No prognostic significance of immunophenotypic changes at the end of remission induction therapy in children with B-lineage acute lymphoblastic leukemia.
    Dai Q; Liu X; Yang H; Guo S; Wang Y; Peng L; Ye L; Chen L; Lai C; Chen Q; Zhang G; Jiang Y
    Leuk Res; 2018 May; 68():57-61. PubMed ID: 29544133
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Flow Cytometry Based MRD and Its Impact on Survival Outcome in Children and Young Adults with ALL: A Prospective Study from a Tertiary Cancer Centre in Southern India.
    Panda SS; Radhakrishnan V; Ganesan P; Rajendranath R; Ganesan TS; Rajalekshmy KR; Bhola RK; Das H; Sagar TG
    Indian J Hematol Blood Transfus; 2020 Apr; 36(2):300-308. PubMed ID: 32425381
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical Significance of Minimal Residual Disease at the End of Remission Induction Therapy in Childhood Acute Lymphoblastic Leukemia.
    Jovanovska A; Martinova K; Kocheva S; Trajkova-Antevska Z; Coneska-Jovanova B; Panovska-Stavridis I; Stankovikj S; Trajkova S; Dimovski A
    Open Access Maced J Med Sci; 2019 Sep; 7(17):2818-2823. PubMed ID: 31844443
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Implementation of a simplified flow cytometric assays for minimal residual disease monitoring in childhood acute lymphoblastic leukemia.
    Vinhas E; Lucena-Silva N; Pedrosa F
    Cytometry B Clin Cytom; 2018 Jan; 94(1):94-99. PubMed ID: 27342632
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical significance of dynamic monitoring the minimal residual disease in childhood B-lineage acute lymphoblastic leukemia by multiparameter flow cytometry].
    Guo DD; Zhao WL; Zhang YL; Pang L; Che L; He HL; Chai YH; Ji ZH; Ji XQ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Dec; 20(6):1346-51. PubMed ID: 23257430
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic value of immunophenotypic detection of minimal residual disease in acute lymphoblastic leukemia.
    Ciudad J; San Miguel JF; López-Berges MC; Vidriales B; Valverde B; Ocqueteau M; Mateos G; Caballero MD; Hernández J; Moro MJ; Mateos MV; Orfao A
    J Clin Oncol; 1998 Dec; 16(12):3774-81. PubMed ID: 9850021
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients.
    San Miguel JF; Martínez A; Macedo A; Vidriales MB; López-Berges C; González M; Caballero D; García-Marcos MA; Ramos F; Fernández-Calvo J; Calmuntia MJ; Diaz-Mediavilla J; Orfao A
    Blood; 1997 Sep; 90(6):2465-70. PubMed ID: 9310499
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value.
    Vidriales MB; Pérez JJ; López-Berges MC; Gutiérrez N; Ciudad J; Lucio P; Vazquez L; García-Sanz R; del Cañizo MC; Fernández-Calvo J; Ramos F; Rodríguez MJ; Calmuntia MJ; Porwith A; Orfao A; San-Miguel JF
    Blood; 2003 Jun; 101(12):4695-700. PubMed ID: 12586618
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The significance of peripheral blood minimal residual disease to predict early disease response in patients with B-cell acute lymphoblastic leukemia.
    Setiadi A; Owen D; Tsang A; Milner R; Vercauteren S
    Int J Lab Hematol; 2016 Oct; 38(5):527-34. PubMed ID: 27339737
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection of minimal residual disease in B-lineage acute lymphoblastic leukaemia by quantitative flow cytometry.
    Farahat N; Morilla A; Owusu-Ankomah K; Morilla R; Pinkerton CR; Treleaven JG; Matutes E; Powles RL; Catovsky D
    Br J Haematol; 1998 Apr; 101(1):158-64. PubMed ID: 9576196
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The use of receiver operating characteristic analysis for detection of minimal residual disease using five-color multiparameter flow cytometry in acute myeloid leukemia identifies patients with high risk of relapse.
    Al-Mawali A; Gillis D; Lewis I
    Cytometry B Clin Cytom; 2009 Mar; 76(2):91-101. PubMed ID: 18727068
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
    zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H
    Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of minimal residual disease (MRD) monitoring by WT1 quantification between childhood acute myeloid leukemia and acute lymphoblastic leukemia.
    Zhang R; Yang JY; Sun HQ; Jia H; Liao J; Shi YJ; Li G
    Eur Rev Med Pharmacol Sci; 2015; 19(14):2679-88. PubMed ID: 26221900
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical value of minimal residual disease detection by flow cytometry in childhood B-cell acute lymphoblastic leukemia].
    Chang L; Zhang G; Shi H; Ye L; Jiang YM
    Zhongguo Dang Dai Er Ke Za Zhi; 2014 Dec; 16(12):1245-9. PubMed ID: 25523574
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.